Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. Nuclear & Precision Health Solutions has 40+ years of expertise and is a national source for both SPECT and PET radiopharmaceuticals, operating the largest network of 130 pharmacies, 30+ cyclotron facilities, and the only Alpha contract manufacturing site in the United States.
Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.
Evergreen Theragnostics was founded in 2019 to fill a need for high-quality and high-reliability manufacturing of centrally distributed radiopharmaceuticals, including therapeutics and antibody based radiopharmaceuticals. Our focus is on late stage clinical trials and commercial supply. Our state-of-the-art full-GMP facility, located in New Jersey, USA is near Newark International Airport and will be opening in 2021.
Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis, pharmaco-imaging & artificial intelligence, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in imaging and targeted radiotherapies.
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal imaging platforms are an open door for non-invasive techniques to understand the pharmacology of your compound in less than 6 months. Finally, we have a unique offering dedicated to pre-clinical evaluation of TRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess systemic radiotherapy efficacy.
Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of immunotherapeutics to pharma and biotech.